- Home
- INFU vs EDIT Comparison
INFU vs EDIT Comparison
Compare INFU & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFU | EDIT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.8M | 206.0M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | INFU | EDIT |
|---|---|---|
| Price | $10.65 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $15.00 | $4.92 |
| AVG Volume (30 Days) | 80.1K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | 37.50 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $143,436,000.00 | $31,937,000.00 |
| Revenue This Year | $3.20 | N/A |
| Revenue Next Year | $7.31 | N/A |
| P/E Ratio | $33.32 | ★ N/A |
| Revenue Growth | 6.36 | ★ 132.64 |
| 52 Week Low | $4.66 | $1.29 |
| 52 Week High | $11.04 | $4.54 |
Technical Indicators
Market Signals| Indicator | INFU | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 48.33 |
| Support Level | $8.52 | $1.95 |
| Resistance Level | $10.84 | $3.17 |
| Average True Range (ATR) | 0.39 | 0.26 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 78.32 | 17.95 |
Price Performance
Historical ComparisonAbout INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.